CXCL13: A Prognostic Marker in Multiple Sclerosis
In the demyelinating autoimmune disease multiple sclerosis (MS) there is a great need for validated prognostic biomarkers that can give information about both prognosis and disease course. So far only clinical parameters have been shown to predict future outcome. CXCL13 is a potent B cell chemoattra...
Main Author: | Havervall, Carolina |
---|---|
Format: | Others |
Language: | English |
Published: |
Södertörns högskola, Institutionen för livsvetenskaper
2010
|
Subjects: | |
Online Access: | http://urn.kb.se/resolve?urn=urn:nbn:se:sh:diva-3656 |
Similar Items
-
Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on “Chemokine CXCL13 in serum, CSF, and blood–CSF barrier function”
by: Krista D. DiSano, et al.
Published: (2021-02-01) -
Peripheral neuropathy due to neuroborreliosis: Insensitivity for CXCL13 as early diagnostic marker
by: Kristina Gubanova, et al.
Published: (2021-04-01) -
Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
by: Georg Pilz, et al.
Published: (2020-02-01) -
CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance
by: Ilias Masouris, et al.
Published: (2021-03-01) -
CXCL13 levels are more increased in cerebrospinal fluid and plasma of patients with acute infectious than in non-infectious diseases of the central nervous system
by: Țilea Brîndușa, et al.
Published: (2017-03-01)